Company intelligence / Profile preview

Medesis Pharma

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Recent encouraging results in Alzheimer's disease reported on September 20, 2024. The company reported earnings results for the half year ended June 30, 2024 on November 12, 2024.

Therapeutic areas: OtherOncologyNeurology
Modalities: Drug delivery technology
Industry: Biotech

Drug pipeline

3 assets

NanoLithium NP03

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Medesis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medesis Pharma.

Explore the full profile